QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has announced plans to strengthen its automated sample preparation portfolio with three new instruments set to launch between 2025 and 2026. The new systems aim to deliver enhanced efficiency and sustainability for laboratories worldwide while addressing different customer segments across the spectrum of throughput needs.
Next-Generation QIAsymphony Set for 2025 Launch
The QIAsymphony Connect, the next generation of QIAGEN's flagship platform with over 3,300 cumulative placements globally, is progressing toward a phased launch beginning in 2025. Early customer sessions are already being scheduled at industry events, including the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) conference in Vienna in April 2025.
The system is designed to address pathogen nucleic acid extraction and various other applications, including liquid biopsy for non-invasive cancer detection, as well as oncology, genomics, and clinical research workflows. With the capacity to process up to 96 samples simultaneously, the QIAsymphony Connect features improved automation capabilities for sample tracking, higher yield for increased assay sensitivity, and enhanced digital connectivity.
Notably, the system will be compatible with QIAsphere, QIAGEN's cloud-based platform that enables remote monitoring, software updates, and instrument status tracking. The company is designing the system for in vitro diagnostic (IVD) use globally, which will enable compliant workflows in most countries, including the United States and Europe.
High-Throughput QIAsprint Connect Targets 2026 Release
The QIAsprint Connect, scheduled for launch in 2026, represents QIAGEN's entry into the automated high-throughput sample processing market. Early demonstrations have showcased the system's ability to process up to 192 samples per run with less than 30 minutes of hands-on time, enabling laboratories to scale up to 600 samples per day.
The system supports both pre-programmed and customizable protocols, with consumables designed with sustainability in mind—reducing plastic waste by up to 50%. This environmental consideration aligns with growing demands for more sustainable laboratory practices.
"We were excited to test the QIAsprint. Its user-friendly design and ability to process large sample numbers efficiently is an ideal solution for laboratories like ours," said Kerstin Luxa of the Max Planck Institute for Plant Breeding Research in Cologne, Germany.
The QIAsprint Connect supports a wide range of sample types, including plant, microbial, soil, stool, and human tissues. It is already being used to develop nine different applications, with its flexibility making it suitable for laboratories working across various research areas.
QIAmini Brings Automation to Low-Throughput Labs
Also slated for a 2026 launch, the QIAmini will expand QIAGEN's automation portfolio into the low-throughput segment. This cost-effective system offers smaller laboratories and those with lower batch sizes an entry point into automation while maintaining the reliability of QIAGEN's trusted kits.
Designed to replace tedious manual pipetting, the QIAmini delivers the reproducibility of automation with the flexibility to scale as needed. It will complement QIAGEN's existing portfolio alongside the updated QIAcube Connect and EZ2 Connect systems, providing automation options for even smaller-scale workflows.
Strategic Portfolio Expansion
"These new sample preparation systems underscore our commitment to helping labs operate more efficiently, sustainably and flexibly," said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. "With QIAmini, QIAsprint Connect and QIAsymphony Connect, we are supporting customers with new ways to tackle complex challenges—from liquid biopsy to high-throughput screening—with smart, scalable solutions."
These upcoming launches build upon recent enhancements across QIAGEN's automation portfolio, including upgrades to the QIAcube Connect and EZ2 Connect systems. Together, they reflect the company's strategy to provide modular, scalable solutions in sample preparation that match evolving laboratory needs from small research settings to high-volume testing facilities.
Market Position and Company Background
QIAGEN N.V., a Netherlands-based holding company, is a leading global provider of "Sample to Insight" solutions that enable customers to gain valuable molecular insights from biological samples. The company's technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials, with assay technologies making these biomolecules visible and ready for analysis.
With solutions provided to more than 500,000 customers worldwide in molecular diagnostics and life sciences, QIAGEN employed over 5,700 people across more than 35 locations as of December 31, 2024. The company's comprehensive approach includes bioinformatics software and knowledge bases that interpret data to report relevant, actionable insights, with automation solutions tying these components together in seamless and cost-effective workflows.
The strategic expansion of QIAGEN's automated sample preparation portfolio reflects the growing demand for efficient, reliable, and scalable laboratory solutions in an era of increasing sample volumes and complexity in molecular testing.
